WCM
ALXN

Weld Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Weld Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,220
Closed -$469K – 707
2020
Q1 		$469K Sell
5,220
-8,235
-61% -$808K 0.24% 145
2019
Q4 		$1.46M Buy
13,455
+8,857
+193% +$947K 0.28% 107
2019
Q3 		$450K Buy
+4,598
New +$518K 0.08% 414

Other funds holding ALXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Weld Capital Management's ALXN Position: Q2 2020 in Review

Weld Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 5,220 shares — an estimated $469K sold.

Weld Capital Management first reported a position in ALXN in Q3 2019 and held it in 3 quarters. The position peaked at $1.46M in Q4 2019. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • Weld Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Weld Capital Management sold 5,220 Alexion Pharmaceuticals shares in Q2 2020, an estimated $469K.
  • Weld Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Weld Capital Management's Alexion Pharmaceuticals position peaked at $1.46M in Q4 2019.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Weld Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.